scispace - formally typeset
D

David A. Cooper

Researcher at Pfizer

Publications -  965
Citations -  81765

David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.

Papers
More filters
Journal ArticleDOI

Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients

TL;DR: Dual therapy with ATV plus RAL maintained viral suppression in this small group of highly ART-experienced patients, implying no disadvantage from switching to dual therapy.
Journal ArticleDOI

Creation of a drug fund for post-clinical trial access to antiretrovirals.

TL;DR: The proposed revision to paragraph 30 of the Declaration of Helsinki would introduce two main changes: that the physician should make every effort to see that patients receive treatment once it has been approved by appropriate authorities and that the doctor is required to explicitly tell patients if they are unlikely to continue receiving treatment from sponsors after they leave the study.
Journal Article

Gay youth and their precautionary sexual behaviors: the Sydney men and sexual health study.

TL;DR: Although young men in this cohort were more likely to be of unknown serostatus, they were at least as knowledgeable, as attached to gay community, and as precautionary in their sexual behaviors with regular and casual male partners as their older counterparts.
Journal ArticleDOI

Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.

TL;DR: Rosiglitazone has minimal effect on flow-mediated dilation in HIV-infected lipoatrophic adults and despite worsening of the lipid profile, the overall effect of rosig litazone on the cardiovascular risk profile in these subjects was positive.
Journal ArticleDOI

Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia

Cohere in EuroCoord, +176 more
TL;DR: HIV-infected children from SSA but not those from other regions, have a high risk of developing Kaposi sarcoma after cART initiation, and early cart initiation in these children might reduce KS risk.